argenx

argenx SE operates as a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases. It operates from the Netherlands, Belgium, the United States of America, Japan, Switzerland, Germany and France. The firm partnering with academic researchers through its Immunology Innovation Program (IIP), argenx aims to translate immunology breakthroughs into a world-class portfolio of novel antibody-based medicines. It evaluates efgartigimod in multiple serious autoimmune diseases and advancing several earlier stage experimental medicines within its therapeutic franchises. The company was founded by Hans J. W. de Haard, Torsten Dreier, and Tim van Hauwermeiren in 2008 and is headquartered in Breda, the Netherlands.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

argenx SE is a global immunology company, which engages in improving the lives of people suffering from severe autoimmune diseases. It operates through the following geographical segments: United States, Japan, EMEA, and China. The company was founded by Hans J. W. de Haard, Torsten Dreier, and Tim van Hauwermeiren in 2008 and is headquartered in Amsterdam, the Netherlands.

BioMarin Pharmaceutical

Genmab - ADR

Eli Lilly

Let us take a look at some biotech stocks, ARGX, BMRN, LLY and GMAB, which are poised to beat on third-quarter earnings.

4 Biotech Stocks Set to Outpace Q3 Earnings Estimates

argenex SE (ARGX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

argenex SE (ARGX) Upgraded to Buy: Here's Why

October 20 , 2022 Amsterdam , the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that it will host a conference call and audio webcast on Thursday, October 27, 2022 at 2:30 pm CET (8:30 am ET) to discuss its third quarter 2022 financial results and provide a business update.

argenx to Report Third Quarter 2022 Financial Results and Business Update on October 27, 2022

Scientific presentations demonstrate argenx's leadership in FcRn blockade and commitment to innovati ng for patients across multiple neuromuscular diseases

argenx to Highlight Key Programs from Neuromuscular Franchise at Upcoming Medical Meetings

Submission package based on positive data from the Phase 3 ADAPT-SC trial demonstrating noninferiority of subcutaneous (SC) efgartigimod compared to intravenously administered VYVGART® (efgartigimod alfa-fcab) based on total immunoglobulin G (IgG) reduction at day 29

argenx Submits Biologics License Application to U.S. Food and Drug Administration for Subcutaneous Efgartigimod for Treatment of Generalized Myasthenia Gravis

argenx Appoints Camilla Sylvest to Board of Directors

August 31 , 2022 Amsterdam , the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that members of management will participate in a fireside chat at the Wells Fargo Healthcare Conference on Wednesday, September 7, 2022, at 8:00 a.m. E.T. in Boston, MA.

argenx to Present at Wells Fargo Healthcare Conference

Does argenex SE (ARGX) have what it takes to be a top stock pick for momentum investors? Let's find out.

Here's Why argenex SE (ARGX) is a Great Momentum Stock to Buy

VYVGART is the first neonatal Fc receptor (FcRn) blocker approved in Europe for the treatment of adults living with generalized myasthenia gravis ( gMG) who are anti-acetylcholine receptor (AChR) antibody positive

argenx Announces European Commission Approval of VYVGART™ (efgartigimod alfa-fcab) for the Treatment of Generalized Myasthenia Gravis

argenx reported another strong quarter with $74.9 million in Vyvgart net sales. The company added 1,000 new patients in Q2, up from 400 in Q1.

argenx: Another Strong Quarter For Vyvgart

argenx SE (NASDAQ:ARGX ) Q2 2022 Earnings Conference Call July 28, 2022 8:30 AM ET Company Participants Beth DelGiacco - VP Corporate Communications and IR Tim Van Hauwermeiren - CEO Karl Gubitz - CFO Keith Woods - COO Conference Call Participants Danielle Brill - Raymond James Yaron Werber - Cowen Yatin Suneja - Guggenheim Partners Derek Archila - Wells Fargo Allison Bratzel - Piper Sandler Akash Tewari - Jefferies Matthew Harrison - Morgan Stanley Tazeen Ahmad - Bank of America Securities Thomas Smith - SVB Securities Jason Butler - JMP Securities Alex Thompson - Stifel Joon Lee - Truist Securities Colin White - UBS Douglas Tsao - H. C. Wainwright Joel Beatty - Baird Manos Mastorakis - Deutsche Bank Operator Good morning.

argenx SE (ARGX) CEO Tim Van Hauwermeiren on Q2 2022 Results - Earnings Call Transcript

argenx announces Extraordinary General Meeting of Shareholders on September 8, 2022

argenx Reports Half Year 2022 Financial Results and Provides Second Quarter Business Update

July 21, 2022 Breda, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that it will host a conference call and audio webcast on Thursday, July 28, 2022 at 2:30 pm CET (8:30 am ET) to discuss its half year 2022 financial results and provide a second quarter business update.

argenx to Report Half Year 2022 Financial Results and Second Quarter Business Update on July 28, 2022

100% technical buy signals. 11 new highs and up 15.30% in the last month.

argenx: Biopharma Star

Breda, the Netherlands— June 24 , 2022—argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended European Commission (EC) approval of efgartigimod as an add-on to standard therapy for the treatment of adult patients with generalized myasthenia gravis (gMG) who are anti-acetylcholine receptor (AChR) antibody positive.

argenx Receives Positive CHMP Opinion for Efgartigimod for the Treatment of Adult Patients with Generalized Myasthenia Gravis in Europe

Positive scientific opinion under Early Access to Medicines Scheme (EAMS) will make efgartigimod available to eligible generali z ed myasthenia gravis (gMG) patients in the UK prior to marketing authori z ation

argenx Announces the UK MHRA has Granted Early Access to Efgartigimod for Generalized Myasthenia Gravis

argenx beat Q1 2022 revenue estimates thanks to a strong launch of Vyvgart in generalized myasthenia gravis. The early patient numbers look good compared to the launch of Soliris four years ago.

argenx: A Very Good Start For Vyvgart

argenx Announces Publication of Translational Data of Efgartigimod in Autoimmune Skin Blistering Diseases

Derivatives markets, used by the market-making community to hedge equity market liquidity trade orders, tell by their component structure and prices the subject stock's expected coming price range limits. By comparing today's balance of upside and downside price change prospects with outcome experiences of similar prior forecasts, qualitative comparisons are being made, stock by stock, of investing portfolio candidates.

argenx SE: Again Following Dutch Biotech, Prior Recommendation Near-Term Gain

argenx SE (NASDAQ:ARGX ) Q1 2022 Earnings Conference Call May 5, 2022 8:30 AM ET Corporate Participants Beth DelGiacco - VP Corporate Communications and Investor Relations Tim Van Hauwermeiren - Chief Executive Officer Luc Truyen - Chief Medical Officer Karl Gubitz - Chief Financial Officer Keith Woods - Chief Operating Officer Conference Call Participants Yatin Suneja - Guggenheim Matthew Harrison - Morgan Stanley Tazeen Ahmad - Bank of America Akash Tewari - Jefferies Yaron Werber - Cowen James Gordon - JPMorgan Derek Archila - Wells Fargo Danielle Brill - Raymond James Charles Pitman - Redburn Joon Lee - Truist Securities Allison Bratzel - Piper Sandler Laura Sutcliffe - UBS Joel Beatty - Baird Douglas Tsao - H.C. Wainwright Operator Good morning.

argenx SE (ARGX) CEO Tim Van Hauwermeiren on Q1 2022 Results - Earnings Call Transcript

Argenx SE's (NASDAQ: ARGX) Phase 3 ADVANCE trial of Vyvgart (efgartigimod alfa-fcab) in adults with primary immune thrombocytopenia (ITP) met its primary endpoint.  The ADVANCE trial enrolled 131 adult patients with chronic and persistent ITP.

Argenx's Vyvgart Meets Primary Goal In Late-Stage Bleeding Disorder Study

Study met primary endpoint, demonstrating a higher proportion of sustained platelet response with VYVGART treatment compared to placebo (p=0.0316) ; responders observed across patient types regardless of prior therapy or disease severity

argenx Announces Positive Phase 3 Data from ADVANCE Trial of VYVGART® (efgartigimod alfa-fcab) in Adults with Primary Immune Thrombocytopenia

argenx Reports First Quarter 2022 Financial Results and Provides Business Update

May 4 , 2022 Breda, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that members of management will participate in a fireside chat at the BofA Securities 2022 Healthcare Conference on Wednesday, May 11, 2022 at 10:40 a.m. P.T. in Las Vegas, NV.

News for argenx Stock (ARGX)